This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Therapy Directed by the Primary Physician

Jeffrey L. Probstfield, MD; Donald B. Hunninghake, MD

Arch Intern Med. 1994;154(14):1557-1559.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

CARDIOVASCULAR DISEASES (CVD) and, in particular, coronary heart disease (CHD) remain the leading cause of death and disability in the western world.¹ Elevated plasma low-density lipoprotein cholesterol (LDL-C) and reduced high-density lipoprotein cholesterol (HDL-C) levels are among the most important risk factors for these diseases.² Hydroxymethylglutaryl coenzyme A reductase inhibitors (HMG-CoA-RI), bile acid sequestrants, and nicotinic acid are the major classes of drugs identified for the reduction of elevated total and LDL-C levels in the Adult Treatment Panel II Report.³ Although highly effective, two of these (bile acid sequestrants and nicotinic acid) have substantial side effects and two (bile acid sequestrants and HMG-CoA-RI) have substantial cost. Nicotinic acid has the greatest HDL-raising effect of any agent used to date⁴; lesser effects have been observed with gemfibrozil⁵ and HMG-CoA-RI.⁶ Independent benefit on CVD or CHD risk by increasing plasma levels of HDL has not been . . . [Full Text PDF of this Article]

Author Affiliations
Fred Hutchinson Cancer Research Center Women's Health Initiative Coordinating Center 1124 Columbia St MP 1002 Seattle, WA 98104-6883; Minneapolis, Minn

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?